We believe patients should have immediate access to the latest therapies.
We improve patient access to new therapies with AI HEOR and Market Access Architecture and Forecasting solutions that assess, optimize, and streamline biopharma’s market access and HTA submissions.
No time to wait.
We believe that medical innovators should be reimbursed by payers without delay.
At Loon, we understand the critical impact that delayed reimbursement can have on both medical innovators and the patients they serve. Every day that a groundbreaking therapy waits for reimbursement is a day that patients go without the treatments they need.
Our AI-driven tools and services are designed to optimize the entire market access journey, from value dossier creation to HTA committee forecasting, so innovators can focus on what they do best: developing transformative medical solutions for patients.
Our commitment
We believe that the Health Technology Assessment and reimbursement process shouldn’t be a roadblock to patient access and medical innovation. Instead, it should be a seamless part of the journey from lab to patient.
We are committed to bridging the access gap by accelerating the market access process and ensuring that life-changing therapies reach the market swiftly.
Meet our team
Our team of market access experts, clinicians, epidemiologists, strategists, and AI scientists
Ghayath Janoudi
Founding CEO, Chief Science Officer
Mara Rada
Founding COO, Chief of Strategy
Josip Ivkovic
Chief Technology Officer
Eric Parker
Legal Affairs and Commercialization
Josue Silva
Senior Clinical Research Liaison
Ahmed Soliman
AI Compliance Officer
By leveraging cutting-edge technology and deep expertise in health economics, we empower medical innovators to navigate the complexities of market access with confidence.
Our goal is to reduce the time and uncertainty associated with reimbursement, enabling faster patient access to the therapies they need and ensuring that medical innovators are rewarded promptly for their contributions to advancing healthcare.
Enhance your Market Access with Loon.
- Get Living Systematic Reviews in days
- Forecast reimbursement conditions
- Prepare Living Global Value Dossiers and optimize your HTA submissions with Scenario Simulation
FAQs
What is Loon’s mission in healthcare?
Our mission is to improve patient access to new therapies by accelerating the market access process for biopharma companies. We aim to ensure that groundbreaking therapies reach patients without unnecessary delays caused by the reimbursement and Health Technology Assessment (HTA) processes.
How does Loon help medical innovators with market access?
Loon provides AI-driven tools and services that optimize the entire market access journey. This includes creating value dossiers, forecasting HTA committee decisions, and simulating reimbursement scenarios, enabling medical innovators to navigate complex market access challenges efficiently.
Why is timely reimbursement important for patients and medical innovators?
Timely reimbursement is crucial because every day a therapy is delayed from reaching the market, patients miss out on potentially life-saving treatments. Additionally, delayed reimbursement can hinder medical innovators from continuing their work in developing transformative therapies.
What expertise does the Loon team bring to market access?
Our team comprises experts and industry veterans in market access, clinical research, epidemiology, strategy, and AI. This multidisciplinary team collaborates to provide comprehensive solutions that streamline the market access process and ensure that therapies reach patients quickly.
How does Loon’s technology assist in the Health Technology Assessment (HTA) process?
Our technology helps streamline the HTA process by offering tools like AI Living Systematic Reviews, Living Global Value Dossiers, and Submission Scenario Simulations. These tools allow for efficient and accurate preparation of HTA submissions, enhancing the likelihood of successful and timely market access.
What are Living Systematic Reviews and how do they benefit market access?
Living Systematic Reviews are continuously updated systematic literature reviews of evidence that support market access, policy, and protocol design decisions. By providing up-to-date data, these reviews help ensure that HTA submissions and reimbursement decisions are based on the most current and relevant information, reducing delays and improving patient access to new therapies.